WO2024259070A3 - Récepteurs antigéniques chimériques et leur utilisation - Google Patents

Récepteurs antigéniques chimériques et leur utilisation Download PDF

Info

Publication number
WO2024259070A3
WO2024259070A3 PCT/US2024/033758 US2024033758W WO2024259070A3 WO 2024259070 A3 WO2024259070 A3 WO 2024259070A3 US 2024033758 W US2024033758 W US 2024033758W WO 2024259070 A3 WO2024259070 A3 WO 2024259070A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric antigen
antigen receptors
msln
vectors
binder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033758
Other languages
English (en)
Other versions
WO2024259070A2 (fr
Inventor
Arthur Fridman
Masahisa Handa
Chung-Ming Hsieh
Sujata Singh
Sahba TABRIZIFARD
Sandra Isabel VANEGAS
Srinivas SOMANCHI
Peter Flynn
Heather Raymon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Artiva Biotherapeutics Inc
Original Assignee
Merck Sharp and Dohme LLC
Artiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC, Artiva Biotherapeutics Inc filed Critical Merck Sharp and Dohme LLC
Priority to EP24824132.5A priority Critical patent/EP4727574A2/fr
Publication of WO2024259070A2 publication Critical patent/WO2024259070A2/fr
Publication of WO2024259070A3 publication Critical patent/WO2024259070A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/51—Stomach
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente divulgation concerne des CAR comprenant un liant de mésothéline humaine (MSLN), des polynucléotides et des vecteurs associés, des cellules modifiées, des compositions pharmaceutiques et des thérapies cellulaires.
PCT/US2024/033758 2023-06-14 2024-06-13 Récepteurs antigéniques chimériques et leur utilisation Ceased WO2024259070A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24824132.5A EP4727574A2 (fr) 2023-06-14 2024-06-13 Récepteurs antigéniques chimériques et leur utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508195P 2023-06-14 2023-06-14
US63/508,195 2023-06-14

Publications (2)

Publication Number Publication Date
WO2024259070A2 WO2024259070A2 (fr) 2024-12-19
WO2024259070A3 true WO2024259070A3 (fr) 2025-04-17

Family

ID=93852897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033758 Ceased WO2024259070A2 (fr) 2023-06-14 2024-06-13 Récepteurs antigéniques chimériques et leur utilisation

Country Status (3)

Country Link
EP (1) EP4727574A2 (fr)
TW (1) TW202504914A (fr)
WO (1) WO2024259070A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3567049A4 (fr) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210269537A1 (en) * 2018-08-29 2021-09-02 Nanjing Legend Biotech Co. Ltd. Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
WO2021207242A2 (fr) * 2020-04-07 2021-10-14 Fred Hutchinson Cancer Research Center Molécules de liaison à l'antigène anti-mésothéline et leurs utilisations
US20220370497A1 (en) * 2020-08-20 2022-11-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210269537A1 (en) * 2018-08-29 2021-09-02 Nanjing Legend Biotech Co. Ltd. Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
WO2021207242A2 (fr) * 2020-04-07 2021-10-14 Fred Hutchinson Cancer Research Center Molécules de liaison à l'antigène anti-mésothéline et leurs utilisations
US20220370497A1 (en) * 2020-08-20 2022-11-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers

Also Published As

Publication number Publication date
WO2024259070A2 (fr) 2024-12-19
EP4727574A2 (fr) 2026-04-22
TW202504914A (zh) 2025-02-01

Similar Documents

Publication Publication Date Title
WO2024259070A3 (fr) Récepteurs antigéniques chimériques et leur utilisation
MX2025010458A (es) Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
ZA202007393B (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
WO2021108661A3 (fr) Récepteurs antigéniques chimériques et leurs utilisations
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
ZA202005556B (en) Cartyrin compositions and methods for use
SG11201906780SA (en) Bcma-targeting antibody and use thereof
WO2023280307A9 (fr) Compositions de il-15 mutant et procédés associés
PH12021551861A1 (en) Constitutively active chimeric cytokine receptors
EP4527466A3 (fr) Récepteurs antigéniques chimériques anti-dll3 et leurs utilisations
PH12022551580A1 (en) Anti-ctla-4 antibody and use thereof
WO2019097305A3 (fr) Matériaux et procédés de génie cellulaire et leurs utilisations en immuno-oncologie
WO2020159754A3 (fr) Anticorps spécifiques à cd44
MY201065A (en) Constructs specifically recognizing glypican 3 and uses thereof
MX2024007390A (es) Anticuerpo completamente humanizado y receptor de antigeno quimerico (car) dirigido al subtipo d de la familia c5 del receptor acoplado a proteina g (gprc5d) y usos del mismo.
EP4106774A4 (fr) Thérapie par lymphocytes t à récepteurs antigéniques chimériques
WO2023081808A3 (fr) Lymphocytes t anti-mésothéline car sécrétant des team et leurs méthodes d'utilisation
WO2022204129A8 (fr) Récepteur chimérique de co-stimulation de cd38 et ses utilisations
WO2024073723A3 (fr) Anticorps anti-cd122 et leurs utilisations
WO2022251120A3 (fr) Récepteur antigénique chimérique
WO2020172643A3 (fr) Récepteurs antigéniques chimériques d'immunosurveillance artificielle (ai-car) et cellules les exprimant
WO2023091954A3 (fr) Antigène cd45 à spécificité pan-leucocytaire génétiquement modifié pour faciliter une thérapie de lymphocytes t car
MX2021015076A (es) Composiciones de virus adeno-asociados para transferencia del gen de la enzima lisosomal arilsulfatasa-a (arsa) y metodos de uso de las mismas.
WO2020070678A3 (fr) Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
BR112021013180A2 (pt) Composição farmacêutica, vetor viral não replicante, e, método para prover terapia celular adotiva

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824132

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024824132

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024824132

Country of ref document: EP

Effective date: 20260114

ENP Entry into the national phase

Ref document number: 2024824132

Country of ref document: EP

Effective date: 20260114

ENP Entry into the national phase

Ref document number: 2024824132

Country of ref document: EP

Effective date: 20260114

ENP Entry into the national phase

Ref document number: 2024824132

Country of ref document: EP

Effective date: 20260114

WWP Wipo information: published in national office

Ref document number: 2024824132

Country of ref document: EP